Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan for cognitive impairment in Parkinson's disease
2016-000679-25Phase 2Completed
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Mar 2016
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Candesartan with Placebo (2 arms). Primary endpoint: Change in Parkinson's Disease-Cognitive Rating Scale (PD-CRS). Started Mar 2016; status: completed.
02
Drugs
candesartan
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2016-000679-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000679-25.